Skip to Main Content
Table 2—

Age-standardized prevalence of known and newly detected type 2 diabetes using 1999 and 1985 World Health Organization criteria and 1997 American Diabetes Association criteria among European, African-Caribbean, and Pakistani individuals aged 35–79 years

European
African-Caribbean
Pakistani
Total
MenWomenMenWomenMenWomenMenWomen
Number screened 222 259 180 188 67 65 517 546 
Known diabetes 8.0 [18] 3.7 [11] 15.7 [36] 16.2 [28] 14.0 [9] 18.2 [12] 11.4 [69] 9.2 [55] 
 (4.7–11.3) (1.5–5.9) (10.7–20.7) (11.5–20.9) (5.7–22.3) (8.8–27.6) (8.8–14.0) (7.0–11.4) 
Glucose tested (n66 83 76 95 52 52 206 243 
New diabetes* 14.1 [12] 16.8 [14] 9.2 [7] 6.0 [7] 18.0 [9] 21.9 [11] 13.5 [29] 12.9 [32] 
 (WHO 1999) (5.7–22.5) (8.8–24.9) (2.7–15.7) (1.2–10.7) (7.6–28.5) (10.7–33.2) (8.9–18.2) (8.7–17.1) 
Known and new 20.8 [30] 19.9 [25] 23.4 [43] 20.8 [35] 29.9 [18] 35.7 [23] 23.3 [98] 20.8 [87] 
 (WHO 1999) (15.5–26.1) (15.1–24.8) (17.2–29.6) (15.0–26.6) (19.0–40.9) (24.0–47.3) (19.6–26.9) (17.4–24.2) 
Minimum prevalence 12.4 [30] 9.2 [25] 19.6 [43] 19.0 [35] 28.0 [18] 35.3 [23] 16.9 [98] 14.9 [87] 
 (8.0–16.7) (5.7–12.8) (13.8–25.4) (13.4–24.7) (17.3–38.8) (23.6–46.9) (13.7–20.2) (12.0–17.9) 
Known and new 18.0 [25] 11.8 [18] 23.7 [42] 20.9 [33] 26.2 [15] 36.4 [22] 20.9 [89] 18.4 [77] 
 (WHO 1985) (13.3–22.7) (8.11–15.5) (17.9–29.5) (15.7–26.1) (15.7–36.7) (24.7–48.1) (17.6–24.2) (15.4–21.4) 
Known and new 19.2 [28] 18.8 [24] 22.9 [42] 18.3 [32] 22.2 [14] 26.7 [14] 20.7 [91] 17.2 [77] 
 (ADA 1997) (14.4–24.0) (14.3–23.3) (17.1–28.7) (13.3–23.3) (12.2–32.2) (15.9–37.5) (17.4–24.0) (14.3–20.1) 
European
African-Caribbean
Pakistani
Total
MenWomenMenWomenMenWomenMenWomen
Number screened 222 259 180 188 67 65 517 546 
Known diabetes 8.0 [18] 3.7 [11] 15.7 [36] 16.2 [28] 14.0 [9] 18.2 [12] 11.4 [69] 9.2 [55] 
 (4.7–11.3) (1.5–5.9) (10.7–20.7) (11.5–20.9) (5.7–22.3) (8.8–27.6) (8.8–14.0) (7.0–11.4) 
Glucose tested (n66 83 76 95 52 52 206 243 
New diabetes* 14.1 [12] 16.8 [14] 9.2 [7] 6.0 [7] 18.0 [9] 21.9 [11] 13.5 [29] 12.9 [32] 
 (WHO 1999) (5.7–22.5) (8.8–24.9) (2.7–15.7) (1.2–10.7) (7.6–28.5) (10.7–33.2) (8.9–18.2) (8.7–17.1) 
Known and new 20.8 [30] 19.9 [25] 23.4 [43] 20.8 [35] 29.9 [18] 35.7 [23] 23.3 [98] 20.8 [87] 
 (WHO 1999) (15.5–26.1) (15.1–24.8) (17.2–29.6) (15.0–26.6) (19.0–40.9) (24.0–47.3) (19.6–26.9) (17.4–24.2) 
Minimum prevalence 12.4 [30] 9.2 [25] 19.6 [43] 19.0 [35] 28.0 [18] 35.3 [23] 16.9 [98] 14.9 [87] 
 (8.0–16.7) (5.7–12.8) (13.8–25.4) (13.4–24.7) (17.3–38.8) (23.6–46.9) (13.7–20.2) (12.0–17.9) 
Known and new 18.0 [25] 11.8 [18] 23.7 [42] 20.9 [33] 26.2 [15] 36.4 [22] 20.9 [89] 18.4 [77] 
 (WHO 1985) (13.3–22.7) (8.11–15.5) (17.9–29.5) (15.7–26.1) (15.7–36.7) (24.7–48.1) (17.6–24.2) (15.4–21.4) 
Known and new 19.2 [28] 18.8 [24] 22.9 [42] 18.3 [32] 22.2 [14] 26.7 [14] 20.7 [91] 17.2 [77] 
 (ADA 1997) (14.4–24.0) (14.3–23.3) (17.1–28.7) (13.3–23.3) (12.2–32.2) (15.9–37.5) (17.4–24.0) (14.3–20.1) 

Data are % [n] (95% CI). Age standardized to the 1991 combined male and female population of England and Wales. Note that 255 individuals aged 25–34 years were not included because no comparable Pakistani group had been sampled within this age group (see text).

*

Prevalence in group without known diabetes attending for glucose tolerance testing;

minimum prevalence assuming that those those individuals who did not undergo glucose challenge would be normoglycernic if tested. ADA, American Diabetes Association; WHO, World Health Organization.)

Close Modal

or Create an Account

Close Modal
Close Modal